January 1 – March, 2016
The first quarter in figures
· Total net sales amounted to TSEK 1,066 (1,057).
· The loss after tax amounted to TSEK 11,600 (9,179).
· The loss per share amounted to SEK 1.40 (1.84).
· The cash flow from current operations was negative in the amount of
TSEK 11,247 (9,197).
· Significant margin improvement with gross margin increasing to 26.3% in Q1
(2.6% Q1 15).
Important events during the quarter
· SciBase’s PMA application was accepted on January 14th as complete starting
the formal evaluation process by the FDA. There has been a high level of
interaction between SciBase and the FDA during and continuing after the first
quarter.
· Continued good growth in key market Germany with total sales up 20% and
electrode sales volume up 49%.
· SciBase has signed a distribution agreement for Switzerland with CDP SWISS
AG. The sales and marketing effort of SciBase’s melanoma detection product
Nevisense will initially focus on the nearly 400 dermatologists that work in
private clinics in Switzerland.
· A change in the Company’s board of directors was communicated as Viktor
Dvrota, as a result of his appointment as Head of Investment at Karolinska
Development, has resigned from SciBase’s Board of Directors. Alternate director
Andreas Pennervall will take his place.
Important events after the end of the period
· On April 25th, the Annual Report for 2015 was published.
Apr 1
2015 -
Jan 1 Mar 31 Jan 1 - Dec 31
- Mar 2016
31
THE GROUP 2016 2015 Rolling 2015
-12
Net sales, SEK ths 1 066 1 057 4 160 4 151
Gross margin, % 26,3% 2,6% 8,5% 2,5%
Equity/Asset ratio, % 94,4% 73,0% 94,4% 95,1%
Net indebtness, multiple 0,06 0,37 0,06 0,05
Cash equivalents, SEK ths 122 17 122 241 133 736
241 313
Cashflow from operating -11 -9 -48 638 -46 588
activities, SEK ths 247 197
Earnings per share (before -1,40 -1,84 -5,68 -6,01
and after dilution), SEK*
Shareholder's equity per 16,19 4,71 17,34 21,09
share, SEK*
Average number of shares, 8 285 4 985 7 735 6 910
000'*
Number of shares at closing 8 285 4 985 8 285 8 285
of period, 000'*
Share price at end of 23,50 - 23,50 31,00
period, SEK
Average number of employees 18 14 15 14
*Adjusted for in May 2015
performed reversed split,
40:1
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”).
Avanza is the certified advisor. Further information is available on
www.scibase.com.
SciBase Holding AB is required to disclose the information provided herein
pursuant to the Securities Markets Act and/or the Financial Instruments Trading
Act. The information was submitted for publication at 8 am on May 13, 2016.
For further information please contact:
Simon Grant, CEO, tele : 46 72 887 43 99
Michael Colérus, CFO, tele : 46 70 341 34 72
Interim Report
| Source: Scibase Holding AB
Attachments
